Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

NCT01526889 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-infectious Intermediate Uveitis
Non-infectious Posterior Uveitis
Non-infectious Panuveitis

Interventions

DRUG: LFG316
DRUG: Conventional Therapy

Sponsor

Novartis Pharmaceuticals